Brief: CervoMed Announces Presentation Of Biomarker Data From AscenD-LB Phase 2a Trial, Preclinical Data
05/03/2024 13:41
March 5 (Reuters) - CervoMed Inc CRVO.O :
* CERVOMED ANNOUNCES PRESENTATION OF BIOMARKER DATA FROM THE
ASCEND-LB PHASE 2A TRIAL AND PRECLINICAL DATA SUPPORTING
POTENTIAL OF NEFLAMAPIMOD IN TAU-MEDIATED DISEASE AT AD/PD ™
2024
* CERVOMED INC - NEFLAMAPIMOD LED TO SIGNIFICANT REDUCTION
COMPARED TO PLACEBO IN PLASMA LEVELS OF GLIAL FIBRILLARY ACIDIC
PROTEIN
* CERVOMED INC - -NEFLAMAPIMOD EFFECTS ON GFAP CORRELATED TO
CLINICAL OUTCOMES ASSESSED BY CDR SUM OF BOXES (CDR-SB)
Source text for Eikon: ID:nGNXbQvxMB
Further company coverage: CRVO.O
((Reuters.Briefs@thomsonreuters.com;))